KAMILLA Trial Shows Practice-Changing Safety/Efficacy for HER2+ mBC
June 24th 2021Rachel Wuerstein, MD, discusses the clinical implications of the results of the KAMILLA trial, which evaluates the benefit of trastuzumab emtansine in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.
Watch
Unmet Needs and Future Directions in Extensive-Stage SCLC
June 21st 2021Hossein Borghaei, DO, shares insights regarding future directions and current unmet needs in extensive-stage small cell lung cancer. He provides advice to researchers about the importance of clinical trials in the setting of extensive-stage small cell lung cancer.
Watch
First-Line Treatment Recommendations for ES-SCLC
June 21st 2021Hossein Borghaei, DO, reviews the currently accepted first-line treatment recommendation for extensive-stage small cell lung cancer: a triple combination of carboplatin, etoposide, and a checkpoint inhibitor (atezolizumab or durvalumab). He provides an overview of the IMpower and CASPIAN trials.
Watch
Tucatinib/Capecitabine/Trastuzumab Studied in HER2+ Breast Cancer With LMD
June 17th 2021Debu Tripathy, MD, discusses the TBCRC049 study investigating the use of tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.
Watch
Important Safety Data Evaluated in Meta-Analysis of Myelofibrosis
June 15th 2021Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.
Watch
Mirvetuximab Soravtansine Plus Bevacizumab Yields High Responses in Platinum-Agnostic Ovarian Cancer
June 10th 2021David M. O’Malley, MD, discusses final analysis data from the phase 1b FORWARD II trial of mirvetuximab soravtansine plus bevacizumab as treatment of patients with platinum-agnostic ovarian cancer.
Watch